泽璟制药：与艾伯维就ZG006的开发和商业化权益达成全球战略合作与许可选择权协议 后续有资格获得最高达10.75亿美元的里程碑付款

Core Viewpoint - Zai Jian Pharmaceutical has entered into a strategic collaboration and licensing agreement with AbbVie for the global development and commercialization of ZG006 (Alveltamig), retaining rights in Greater China while granting AbbVie exclusive rights outside this region [1] Group 1: Agreement Details - AbbVie will pay Zai Jian a $100 million upfront payment, with potential milestone payments of up to $60 million based on clinical progress [1] - If AbbVie exercises its licensing option, Zai Jian could receive up to $1.075 billion in milestone payments and tiered royalties ranging from high single digits to mid-double digits on net sales outside Greater China [1] Group 2: Product Information - ZG006 is a novel trispecific T-cell engager targeting DLL3, currently in late-stage clinical development for small cell lung cancer and other DLL3-expressing malignancies [1] - The drug has received clinical trial approval from the FDA and NMPA, and has been designated as a breakthrough therapy for relapsed or progressive advanced small cell lung cancer and DLL3-positive neuroendocrine carcinoma by NMPA [1] - ZG006 has also been granted orphan drug designation by the FDA [1]